Posted by Michael Wonder on 18 Apr 2023
AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec
17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of medications of the Régie de l'assurance maladie du Québec (RAMQ) for the treatment of schizophrenia.
This announcement comes 12 months after the approval of Vraylar by Health Canada, bringing a new treatment option to Canadians living with schizophrenia.
